Compare Gilead Sciences, Inc. (GILD) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Huntington Bancshares Incorporated — how do they compare? Gilead Sciences, Inc. trades at $133.43 (market cap $163.51B), while Huntington Bancshares Incorporated trades at $18.46 (market cap $36.74B). The key difference: Gilead Sciences, Inc. is far larger — about 4.5× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.42%). Which is the better fit depends on your goals.
| GILD | HBAN | |
|---|---|---|
Market Cap | $163.51B | $36.74B |
Sector | Health | Financials |
52-Week High | $155.80 | $19.27 |
52-Week Low | $108.22 | $15.02 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 3.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Huntington Bancshares (HBAN) trades at $17.85, down 0.45% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q1 2026 EPS of $0.25, beating expectations, and revenue growth to $8.13B in 2025. Analysts maintain a consensus price target of $20.25, with 49% recommending Buy. Recent news highlights expansion in Texas and strong Q1 results, though integration risks from acquisitions remain a focus.
HBAN presents a moderate growth opportunity with a P/E of 13.94 and ROE of 8.6%, supported by earnings beats and strategic expansions. Key risks include competitive pressures in regional banking and execution challenges from M&A activity. The stock's upside to the consensus target suggests potential appreciation, but investors should weigh margin trends and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
